Is there a standard of care for relapsed AML?

被引:25
作者
Medeiros, Bruno C. [1 ]
机构
[1] Stanford Univ, Sch Med, 875 Blake Wilbur Dr, Stanford, CA 94305 USA
关键词
Acute myeloid leukemia; AML; Gemtuzumab ozogamicin; Enasidenib; Gilteritinib; Ivosidenib; Quizartinib; Relapse; Refractory; ACUTE MYELOID-LEUKEMIA; PLUS CYTARABINE; ADULT PATIENTS;
D O I
10.1016/j.beha.2018.09.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite advances in treatment for acute myeloid leukemia (AML), the prognosis for patients with relapsed disease is extremely poor. The median overall survival for patients with relapsed AML ranges from 4-6 months and long-term survival from the time of relapse ranges from 5%-20%. Much of the difficulty in establishing a standard of care for relapsed AML is that the disease is clinically and genomically diverse. Nevertheless, significant progress has been made over the past 12 months with the approval of several agents, and the expectation is that additional therapies will be available soon. A brief review follows on the progress made in establishing a standard of care for relapsed AML.
引用
收藏
页码:384 / 386
页数:3
相关论文
共 17 条
[1]   Prognostic index for adult patients with acute myeloid leukemia in first relapse [J].
Breems, DA ;
Van Putten, WLJ ;
Huijgens, PC ;
Ossenkoppele, GJ ;
Verhoef, GEG ;
Verdonck, LF ;
Vellenga, E ;
De Greef, G ;
Jacky, E ;
Van der Lelie, J ;
Boogaerts, MA ;
Löwenberg, B .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1969-1978
[2]   Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission [J].
Burnett, Alan K. ;
Goldstone, Anthony ;
Hills, Robert K. ;
Milligan, Donald ;
Prentice, Archie ;
Yin, John ;
Wheatley, Keith ;
Hunter, Ann ;
Russell, Nigel .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) :1293-1301
[3]   A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study [J].
Chevallier, P. ;
Labopin, M. ;
Turlure, P. ;
Prebet, T. ;
Pigneux, A. ;
Hunault, M. ;
Filanovsky, K. ;
Cornillet-Lefebvre, P. ;
Luquet, I. ;
Lode, L. ;
Richebourg, S. ;
Blanchet, O. ;
Gachard, N. ;
Vey, N. ;
Ifrah, N. ;
Milpied, N. ;
Harousseau, J-L ;
Bene, M-C ;
Mohty, M. ;
Delaunay, J. .
LEUKEMIA, 2011, 25 (06) :939-944
[4]  
Cortes J, 2018, QUIZARTINIB SIGNIFIC
[5]   Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML [J].
DiNardo, C. D. ;
Stein, E. M. ;
de Botton, S. ;
Roboz, G. J. ;
Altman, J. K. ;
Mims, A. S. ;
Swords, R. ;
Collins, R. H. ;
Mannis, G. N. ;
Pollyea, D. A. ;
Donnellan, W. ;
Fathi, A. T. ;
Pigneux, A. ;
Erba, H. P. ;
Prince, G. T. ;
Stein, A. S. ;
Uy, G. L. ;
Foran, J. M. ;
Traer, E. ;
Stuart, R. K. ;
Arellano, M. L. ;
Slack, J. L. ;
Sekeres, M. A. ;
Willekens, C. ;
Choe, S. ;
Wang, H. ;
Zhang, V. ;
Yen, K. E. ;
Kapsalis, S. M. ;
Yang, H. ;
Dai, D. ;
Fan, B. ;
Goldwasser, M. ;
Liu, H. ;
Agresta, S. ;
Wu, B. ;
Attar, E. C. ;
Tallman, M. S. ;
Stone, R. M. ;
Kantarjian, H. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2386-2398
[6]   Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing [J].
Ding, Li ;
Ley, Timothy J. ;
Larson, David E. ;
Miller, Christopher A. ;
Koboldt, Daniel C. ;
Welch, John S. ;
Ritchey, Julie K. ;
Young, Margaret A. ;
Lamprecht, Tamara ;
McLellan, Michael D. ;
McMichael, Joshua F. ;
Wallis, John W. ;
Lu, Charles ;
Shen, Dong ;
Harris, Christopher C. ;
Dooling, David J. ;
Fulton, Robert S. ;
Fulton, Lucinda L. ;
Chen, Ken ;
Schmidt, Heather ;
Kalicki-Veizer, Joelle ;
Magrini, Vincent J. ;
Cook, Lisa ;
McGrath, Sean D. ;
Vickery, Tammi L. ;
Wendl, Michael C. ;
Heath, Sharon ;
Watson, Mark A. ;
Link, Daniel C. ;
Tomasson, Michael H. ;
Shannon, William D. ;
Payton, Jacqueline E. ;
Kulkarni, Shashikant ;
Westervelt, Peter ;
Walter, Matthew J. ;
Graubert, Timothy A. ;
Mardis, Elaine R. ;
Wilson, Richard K. ;
DiPersio, John F. .
NATURE, 2012, 481 (7382) :506-510
[7]   Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial [J].
Faderl, Stefan ;
Wetzler, Meir ;
Rizzieri, David ;
Schiller, Gary ;
Jagasia, Madan ;
Stuart, Robert ;
Ganguly, Siddhartha ;
Avigan, David ;
Craig, Michael ;
Collins, Robert ;
Maris, Michael ;
Kovacsovics, Tibor ;
Goldberg, Stuart ;
Seiter, Karen ;
Hari, Parameswaran ;
Greiner, Jochen ;
Vey, Norbert ;
Recher, Christian ;
Ravandi, Farhad ;
Wang, Eunice S. ;
Vasconcelles, Michael ;
Huebner, Dirk ;
Kantarjian, Hagop M. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2492-2499
[8]   Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience [J].
Ganzel, Chezi ;
Sun, Zhuoxin ;
Cripe, Larry D. ;
Fernandez, Hugo F. ;
Douer, Dan ;
Rowe, Jacob M. ;
Paietta, Elisabeth M. ;
Ketterling, Rhett ;
O'Connell, Michael J. ;
Wiernik, Peter H. ;
Bennett, John M. ;
Litzow, Mark R. ;
Luger, Selina M. ;
Lazarus, Hillard M. ;
Tallman, Martin S. .
AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (08) :1074-1081
[9]   Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse [J].
Giles, Francis ;
Vey, Norbert ;
DeAngelo, Daniel ;
Seiter, Karen ;
Stock, Wendy ;
Stuart, Robert ;
Boskovic, Darinka ;
Pigneux, Arnaud ;
Tallman, Martin ;
Brandwein, Joseph ;
Kell, Jonathan ;
Robak, Tadeusz ;
Staib, Peter ;
Thomas, Xavier ;
Cahill, Ann ;
Albitar, Maher ;
O'Brien, Susan .
BLOOD, 2009, 114 (19) :4027-4033
[10]   Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse [J].
Kurosawa, Saiko ;
Yamaguchi, Takuhiro ;
Miyawaki, Shuichi ;
Uchida, Naoyuki ;
Sakura, Toru ;
Kanamori, Heiwa ;
Usuki, Kensuke ;
Yamashita, Takuya ;
Okoshi, Yasushi ;
Shibayama, Hirohiko ;
Nakamae, Hirohisa ;
Mawatari, Momoko ;
Hatanaka, Kazuo ;
Sunami, Kazutaka ;
Shimoyama, Manabu ;
Fujishima, Naohito ;
Maeda, Yoshinobu ;
Miura, Ikuo ;
Takaue, Yoichi ;
Fukuda, Takahiro .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11) :1857-1864